The instruction for medical use
of FARINGOSEPTUM medicine
the Trade name
the International unlicensed
name Ambazonum Dosage Form
of the Tablet for resorption with taste of mint of 10 mg
One tablet contains
active agent of Ambazonum monohydrate of 10 mg,
excipients: sucrose, lactoses monohydrate, cocoa, K30 povidone, stearic acid, fragrance mint.
Firm tablets of a cylindrical form, brown color, with integral edges, with the flat smooth pigmented surface, with inscription M on one party
Drugs for treatment of diseases of a throat. Antiseptic agents. Ambazonum.
The ATX R02AA01 code
Antiseptic properties for topical administration in the LOR-expert and stomatology. Has bacteriostatic action. Streptococcus viridans, Pneumococcus is active concerning Streptococcus haemoliticus.
Does not influence intestinal microflora
as a part of complex therapy for acute infectious and inflammatory diseases of an oral cavity and throat
– an ulitis, stomatitis, a tonsillitis, pharyngitis, tonsillitis
– after tonsilectomy and extraction of teeth
the Route of administration and doses
by the Adult on 35 tablets (3050 mg) a day, within 3-4 days
to Children from 14 to 18 years on 1 tablet a day. Course of treatment 34 days. The tablet of Faringoseptum is not swallowed, and hold in a mouth before full resorption. Drug is used right after food (in 15-30 minutes), it is recommended to refrain from food and drink within 2-3 hours after administration of drug
– it is possible in case of hypersensitivity – an itching, skin rash, a Quincke’s edema,
a small tortoiseshell
– saliva coloring (isolated case)
of the Contraindication
– hypersensitivity to Ambazonum or any component of drug
– children’s age up to 14 years
the Medicinal interactions
are not established
Because of the content of sugar, it is recommended to avoid use by the patient with diabetes.
Because of lactose content (150 mg in one tablet), it is recommended to avoid use by the patient with a lactose intolerance, to patients with rare hereditary diseases intolerance of a galactose, lactose – insufficiency or a syndrome of disturbance of absorption
Pregnancy and a lactation
during pregnancy the use of drug is possible if the expected advantage for mother exceeds potential risk for a fruit. In the period of a lactation at use of drug to stop feeding by the child’s breast, in view of a ratio advantage/risk.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
Drug does not affect ability to run the vehicle or potentially dangerous mechanisms.
is not revealed. If accidentally the drug was taken in a high dose, then it is recommended to cause vomiting and to wash out a stomach.
The form of release and packing
On 10 tablets place in blister strip packaging from a transparent colourless foil from aluminum/polyvinylchloride/polyethylene/polyvinylchloride.
On 1 or 2 planimetric pack together with the instruction for use in the state and Russian languages put in a pack from cardboard
to Store at a temperature not over 25C.
To store out of children’s reach!
not to use a period of storage after expiry date.
Producer S.C.TERAPIA S.A., Str. Fabricii, nr 124, Cluj-Napoca 400,632, Romania
the Owner of the registration certificate
of Sun Pharmaceutical Industries Ltd, India
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of the products responsible for post-registration observation of safety of medicine
Representation of Sun Pharmaceutical Industries Ltd in RK
Almaty, Manas St. 32A, BC SAT, office 602